about
Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell lineHaemodynamic changes early in prodromal symptoms of vasovagal syncope.Plasma galanin response to head-up tilt in normal subjects and patients with recurrent vasovagal syncope.Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds.Hypopituitarism after traumatic brain injury.Antiproliferative effects of somatostatin analogs in pituitary adenomas.In vitro testing of new somatostatin analogs on pituitary tumor cells.Systemic illness.Thyroid papillary microcarcinoma: a descriptive and meta-analysis study.Pituitary side effects of old and new drugs.Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells.Protein kinase C: a putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro.Growth hormone excess promotes breast cancer chemoresistance.Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism.Evaluation of hormonal function in a series of incidentally discovered adrenal masses.Predictors of morbidity and mortality in acromegaly: an Italian survey.Blood growth hormone-binding protein levels in premenopausal and postmenopausal women: roles of body weight and estrogen levels.CYP11B2 -344T/C gene polymorphism and blood pressure in patients with acromegaly.Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.Evidence for integrity of the growth hormone/insulin-like growth factor-1 axis in patients with severe head trauma during rehabilitation.Effect of delta-opioid receptor agonist deltorphin on circulating concentrations of luteinizing hormone and follicle stimulating hormone in healthy fertile women.Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy.Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone-releasing hormone.An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro.Occurrence of pituitary dysfunction following traumatic brain injury.Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.Predictors of pituitary dysfunction in patients surviving ischemic stroke.Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome.Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.Role of pituitary tumour transforming gene 1 in medullary thyroid carcinoma.GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatmentDifferential effects of deltorphin on arginine and galanin-induced growth hormone secretion in healthy manClinical Value of Different Responses of Serum Thyroglobulin to Recombinant Human Thyrotropin in the Follow-Up of Patients with Differentiated Thyroid CarcinomaPatients with PTSD after intensive care avoid hospital contact at 2-year follow-upAnterior Pituitary Function May Predict Functional and Cognitive Outcome in Patients with Traumatic Brain Injury Undergoing Rehabilitation
P50
Q28204929-7342E4A5-E9BA-44E6-9A46-02C86AA54C61Q33147904-36A92A5A-88D0-48EF-B2EF-775CCF81AB02Q33148706-C8C91B83-9833-4B76-9932-657EE63817A7Q34616528-8C60141C-F1EC-4A2E-AEFE-BA67199DCF5FQ36119344-95399F6E-0F48-4E05-A070-FEAEFC50B20BQ36480174-39BE5E45-E427-48DE-8F3A-8585A46603E4Q37075120-9DB97A92-1B4A-4ED3-9DA9-7F7364944605Q37135443-8F4E2A3D-24AA-4B62-8FFE-8A6F1AE944C8Q37247453-C3345C29-02A4-4BBB-BCB0-E8883F58389DQ38234756-0160C73F-1F64-43D3-BA31-A9AC5920BD55Q38823093-68EFF2F7-4375-4F62-9C05-BA79C8335DDEQ39388406-3AD84F34-596E-4316-97D9-A092EE6FE05FQ39822484-B4D4DC6B-35EE-4EDE-8C71-1B8267738877Q40043203-9C6864B1-4BBA-4470-BF1D-2D930D06E4D6Q40298829-28188AF7-BCEA-44CA-999F-B5480B15E036Q40386924-163F8FC9-2CA4-48C1-8936-0B96F3D04BAAQ42528877-FF667159-A880-4760-B0B9-12E5E5030247Q43526287-EB7F04A6-47E5-4114-AD4A-1F86109AAA44Q43601791-E73B76B7-D512-421E-9F83-82C2DBE6E2A5Q43608913-39CC730B-CBC5-49D4-B6B8-792332F34D9CQ43793245-EF89CE4F-F05D-41A3-B945-59C0F3F7528BQ44172565-979B0B22-C9FD-47FD-9BCA-C3A8A1205E5EQ44349193-BDCFF57D-57F6-4ACC-8913-4F48DCAC72B5Q44501364-AE8642CC-99E6-4E43-82D1-C41F97B64EC7Q44502668-96184FF7-90A7-44E4-BF34-CF55C9BECBB0Q44550994-CE8E42CF-27F1-47B0-BE39-F1A7AB43F3EEQ44978415-4F05D045-9853-4BFB-9072-7376BF5552BCQ46672459-94FAC730-BC31-42E6-91FB-03152224DED5Q46745830-6ACD1E1F-E735-44A0-A05D-A07A648019D5Q48112282-DB214A87-2A69-4D44-9052-6408B3F07320Q48373900-609F8C82-4324-4D68-9B3D-AF2C6E65AB13Q48457285-9206FCCF-C768-40C2-94B7-D31F310EED59Q50884057-D67431AA-6E37-4642-9862-FAEDA584DF81Q53590645-54260DC1-CA1B-44DA-9F28-AE17E4046106Q54885662-9B4B33AB-3014-42AF-A7CE-D5D1BDAC5E64Q57604220-867FC4DB-EAD8-4050-916C-F6743C5CE2A4Q57959192-B4E1CA26-E152-4EB4-BE26-88E7AD256BE2Q58004598-CDF4C4F5-B72E-4A8B-8A00-2410C1C75856Q59537776-F13FFD7D-3A74-4BED-8299-284E0E7CAA0BQ59537780-EACA3A0A-C098-4226-8ED4-822B821E5BEA
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marta Bondanelli
@ast
Marta Bondanelli
@en
Marta Bondanelli
@es
Marta Bondanelli
@nl
Marta Bondanelli
@sl
type
label
Marta Bondanelli
@ast
Marta Bondanelli
@en
Marta Bondanelli
@es
Marta Bondanelli
@nl
Marta Bondanelli
@sl
prefLabel
Marta Bondanelli
@ast
Marta Bondanelli
@en
Marta Bondanelli
@es
Marta Bondanelli
@nl
Marta Bondanelli
@sl
P106
P1153
6603573784
P21
P31
P496
0000-0001-8071-6559